>> However, the cancer-killing pill Malkas has been developing over the past two decades, AOH1996, targets a cancerous variant of PCNA, a protein that in its mutated form is critical in DNA replication and repair of all expanding tumors<p>But it's still a single pathway. Cancer has abilities to circumvent most pathways, after a time.<p>Targeting multiple pathways will be the answer, but FDA is so slow at allowing multiple-target clinical trials. Keytruda thus far, has been the best to believe in combining with many other products, and get clinical trials going. Sure, they have to partner with competitors, but this (multi-pathways) is the true path to stopping cancer.
There is a new cancer cure every year for more than a decade now but still nothing really substantiates in terms of saving people's lives at scale. This research is promising but authors of such news should feel morally obligated to also mention realistically how far away in future will be the medicine based on this research given that there are people out there with limited time on their hands who might start getting their hopes up by reading these.
Link to paper here: <a href="https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(23)00221-0" rel="nofollow noreferrer">https://www.cell.com/cell-chemical-biology/fulltext/S2451-94...</a>